A modified pharmacokinetic model for platinum disposition in ovarian cancer patients receiving cisplatin.
We have fitted a first-order multicompartment pharmacokinetic model to plasma platinum concentrations measured in nine ovarian cancer patients who received intravenous infusions of cisplatin for 6 h. The time-course of ultrafilterable plasma platinum was similar in all patients studied, and was fitted by a single compartment within the limits of experimental detection. However, the time-course of protein-bound platinum showed marked differences between patients, the differences being explained by distribution to two peripheral compartments. The wide inter-patient variation observed in protein-bound plasma platinum concentrations supports the view that pharmacokinetic modelling should be carried out separately for each patient, since averaging plasma concentrations would have obscured some individual pharmacokinetic characteristics.
South Wales Radiotherapy and Oncology Service, Velindre Hospital, Whitchurch, Cardiff, UK.
H
H
Griffiths
M D
MD
Shelley
R G
RG
Fish
D002945:Cisplatin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy; D010984:Platinum / Q000097:blood*; D011485:Protein Binding
D010984:Platinum; D002945:Cisplatin